Soleno Therapeutics Inc.
Soleno Therapeutics Appoints Jennifer Fulk as New CFO
Summary
On February 25, 2026, Soleno Therapeutics, Inc. announced the appointment of Jennifer Fulk as its new Chief Financial Officer, effective March 2, 2026. Fulk, who has extensive experience in finance roles at Eli Lilly and Talkspace, will succeed James Mackaness, who is retiring by the end of March. Mackaness will continue as a consultant until December 31, 2026. Fulk's compensation includes an annual base salary of $525,000, potential bonuses, stock options, and restricted stock units.
Profitelligence Alerts
Get alerts for SLNO
Be first to know when Soleno Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Soleno Therapeutics Inc.
Soleno Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for rare diseases. Its primary focus lies on the treatment of genetic disorders that have a significant medical need, such as Prader-Willi syndrome, a complex condition that affects the musculoskeletal and endocrine systems. Soleno is committed to pioneering advancements in the pharmaceutical industry by leveraging innovative approaches to drug development. The company's lead treatment candidate, rooted in addressing metabolic and neurobehavioral abnormalities, plays a critical role within its pipeline. Soleno's research and development efforts are concentrated on improving patient outcomes through therapies that target underlying disease mechanisms. Based in Redwood City, California, Soleno Therapeutics Inc. actively collaborates with scientific communities and healthcare providers to enhance its therapeutic offerings. In the financial market, Soleno Therapeutics is notably positioned as part of the healthcare and biotechnology sectors, reflecting its significance in developing treatments that can transform patient care and address unmet medical needs in niche and complex disease areas.
Official SEC Documents
Advertisement